An observational study in Delirium, Postoperative, Cognitive Decline and Dementia, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Massachusetts General Hospital · Observational
Among 81 studies in Emergence Delirium with a site in United States — 19 open to participants now, 20 under way, 2 of them phase 3. Emergence Delirium · United States.
Among the 81 studies in Emergence Delirium with a site in United States, this one is the 10th largest by planned enrollment of the 16 observational ones that give a count, is one of 10 that started in 2023, is one of 16 observational ones, reaches primary completion later than 1 of the 19 other live ones, and was the 57th registered.
752 studies on the registry are indexed under Emergence Delirium; 262 are open to participants now.
Browse Emergence Delirium studies →19 of the 81 studies in Emergence Delirium with a site in United States are open now. Recruiting first, the newest first:
University of Pittsburgh · Sites in United States
Ages 65+
Boston Children's Hospital · Sites in United States
Ages 1–12
The Methodist Hospital Research Institute · Sites in United States
Ages up to 65
Northwestern University · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 143 Emergence Delirium studies recruiting now, 79 (55%) set no upper age limit and 44 (31%) stop at 75 or younger; 34 take children under 18; 24 take healthy volunteers.
This study: 70 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 10 · Phase 4 13
First in 2002; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is close to the median of 164 across 278 observational studies indexed under Emergence Delirium.
Median enrollment 100 across the 65 interventional studies, 217 across the 16 observational. Of the 59 that completed or were terminated, 33 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 81 have an industry lead sponsor. The 10 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,588 studies on the registry; 446 are open to participants now.
Of its 223 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Massachusetts General Hospital has 4 studies filed under Emergence Delirium — fewer than ten, so there is no comparison to draw.
9 of the studies in Emergence Delirium with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06133842Beth Israel Deaconess Medical CenterCEReBral AutorEgulation in Non-cardiac SuRgery and Relationship to Postoperative DeliriUm State | 2026-12 |
| NCT06324955Boston Children's HospitalLanguage During Inhalational Induction | 2027-03 |
| NCT06036095Oregon Health and Science UniversityTotal Intravenous Versus Inhalational Anesthesia- A Geriatric Anesthesia Study | 2027-03-15 |
| NCT07933003Stanford UniversityPrehab-COG: Does Preoperative Exercise Improve Postoperative Cognitive Outcomes? | 2027-06 |
| NCT07672301University of ChicagoTotal Intravenous Anesthesia vs Spinal Anesthesia in Patients Undergoing Unilateral Primary Total Knee Arthroplasty | 2027-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 81 studies in Emergence Delirium with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this prospective cohort study is to assess potential differences in sleep biomarkers in older adult patients undergoing major orthopedic surgery. The main questions it aims to answer are:
Participants will be asked to:
This study is a prospective, observational study designed to identify changes in protein biomarkers levels as a function of delirium incidence and delirium severity scores based on Confusion Assessment Method (CAM) scores from postoperative days 1-3. Additionally, patients will wear an Actiwatch to monitor sleep/circadian rhythm biomarkers. Questionnaires gathering information about sleep, cognition, mood, pain, and physical/social function will be asked throughout the course of the study. There is no intervention being tested in this study. Accepted standard of care involving all clinical procedures, pain management, and anesthesia and surgical care, will be performed within this study. Patients will be contacted remotely at 1-month, 3-months, and 12-months for follow-up visits that will include questionnaires and actigraphy assessments.
If possible, the patient will be enrolled in person where the member of the study team will complete all enrollment procedures if time allows. The baseline procedures will include fitting the Actiwatch, going over Actiwatch usage instructions, and a baseline neurocognitive assessment and questionnaires. If there is not enough time for complete these procedures, or if the patient is approached over the phone, a member of the study team can complete these baseline procedures with the patient remotely. Baseline assessments can be completed over the phone, and the Actiwatch will be mailed directly to the patient's preferred address.
Clinical Data Collection - Clinical data but not limited to including age, sex, body mass index (BMI), length of hospital stay, and surgical details (e.g., surgery duration, anesthesia type, blood loss, complications) will be recorded using passively collected data from the patient's electronic medical record. Information about history of sleep, cognition/neurology, psychiatry, pain management, and physical/social function that cannot be inferred from the patient's medical record will be elicited from the participant directly at the time of the baseline questionnaires.
Actiwatch Data Collection - Patients will wear the Actiwatch continuously for at least seven days but no more than two weeks leading up to surgery. The watch will be distributed with a specific instruction sheet, and the study team will ensure that all questions have been answered. Patients who are consented at the time of their preoperative clinic visit will be given their watch at the time of their appointment. For patients who are consented virtually, the watch will be mailed to their preferred home address. The watch will collect data including sleep duration, regularity, stability and timing of rhythm. Patients will return the watch on the day of surgery. Patients will be asked to wear the watch for one week at the time of their 1-, 3-, and 12-month timepoints as well. Watches will be returned to the participant via mail and a prepaid mailing envelope will be sent with the watch so that the patient can return it at the conclusion of the recording period.
Sleep Diary - Patients will be asked to fill out a sleep diary on the days that they wear the Actiwatch. The diary will ask questions regarding their sleep habits and factors that might affect their ability to fall asleep. The sleep diary should be filled out during the period leading up to the patient's surgery and again at their 1-, 3-, and 12-month follow-up visits.
ECG Data Collection - Electrocardiogram data will be collected using a 4-lead ECG monitor with oximetry. During the inclusion visit, a study staff member will fit the ECG and oximeter to the patient and record for 30 minutes. The device can connect to an app for Bluetooth ECG reading display. Study staff will monitor the live recording to ensure that data is being collected accurately. The ECG-oximetry data can provide information about cardio physiological biomarkers for delirium. This study measure can be taken either at the time of consent (for patients who consent in-person), or in the preoperative holding area on the day of surgery. An additional recording will occur for 30 minutes perioperatively. If either ECG recording cannot be performed, this will not be considered a protocol deviation.
EEG Data Collection - If the anesthesiologist places a SedLine for EEG for clinically-indicated surface level electroencephalogram monitoring while the patient is under general anesthesia, a study staff member may record the data to be used later to explore EEG biomarkers of delirium risk. If the EEG recording cannot be collected, this will not be considered a protocol deviation.
Assessments - The Montreal Cognitive Assessment (MoCA) will be performed during the baseline visit at the preoperative clinic site, or over the phone using the telephonic version (tMoCA). The MoCA will also be completed daily on postoperative days 1, 2, and 3. The long-form of the Confusion Assessment Method (CAM) will be performed at the baseline visit or baseline phone-call and twice daily on postoperative days 1 through 3 (morning and afternoon). In the afternoons during the first three days postoperatively, a standard cognitive assessment will be performed in order to appropriately score the CAM. The postoperative assessments will be performed by a trained member of the study team. The tMoCA will be completed at the 1-month, 3-month, and 12-month follow up periods.
The CAM-long form will be applied twice daily from preoperative day 1 to postoperative day 3 to evaluate cognitive changes in each patient, and the peak delirium severity score will be used for comparative analyses. CAM scores will be recorded for each patient to determine if the criteria for a positive delirium screen have been met. The Montreal Cognitive Assessment (MoCA) will also be used to evaluate cognitive differences at baseline during the preoperative evaluation.
Additionally, subjects will complete sleep disturbance questionnaires at the time of their baseline visit and at 1-, 3-, and 12 months after surgery including the Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS), and a chronotype questionnaire (only asked at baseline). The Geriatric Depression Scale (GDS) and Generalized Anxiety Disorder 7 (GAD-7) questionnaires will be administered to gather information about the patient's mood. The PROMIS Pain Interference Short Form questionnaire and a Verbal Rating Scale will be used to assess pain experienced by the patients. The Functional Activities Questionnaire (FAQ), FRAIL Scale, and UCLA Loneliness Scale will be administered to assess physical and social function of the patient. These questionnaires can be administered at any point during the baseline and 1-month, 3-month, and 12-month follow-up periods (4 administrations, 1 at each period) at the hospital, over the phone, or via a secure REDCap survey patients can fill out remotely.
Patients will be contacted over the phone or through email across the course of participation to clarify study procedures and to coordinate virtual follow-up visits as necessary.
To assess for the impact of nutrition on the collected blood samples, a nutrition assessment will be performed prior to blood collection.
Details regarding patient-centered clinical outcomes, including delirium onset, delirium severity, mortality, and hospital length of stay, will be collected using our electronic medical record.
Blood Collection:
First blood draw (20ml): Preoperative day 0 (0-2 hours before surgery)
Second blood draw (10ml): Postoperative day 1 (± 1 day)
When possible, blood collection will be performed while the patient is under general anesthesia and be extracted from an indwelling line to minimize patient discomfort. Trained study staff may perform the phlebotomy, but we will not consider it a protocol deviation if blood cannot be collected due to insufficient staff training, IV availability, or patient refusal. A one-day window will be employed for the postoperative assessment to enhance collection efforts if a sample cannot be obtained on postoperative day one.
Targeted protein screens and metabolomics analysis will then be used to analyze blood to determine the relative metabolic and inflammatory protein abundance and steady-state metabolite levels at each timepoint.
Coded Samples: All blood samples will be assigned a unique sample ID, containing no identifiers that can be associated with the subject. The sample ID will be used for all data analysis and provided to the core facilities for analyses. The sample ID and associated patient MRN crosswalk will be stored in a secure and locked spreadsheet and only available to the MGB IRB-approved study team.
Sample Processing: Whole-blood samples will be collected and immediately processed for plasma and DNA isolation in the laboratory. Briefly, blood collected preoperatively will be transferred to a plasma and buffy coat separator tube with clot factor (EDTA - purple top tube), followed by centrifugation at 3000rpm for 30 minutes. The supernatant (plasma) and buffy coat (DNA) will then be collected, aliquoted, and stored at -80°C until further processing. Blood collected postoperatively will be transferred to a plasma separator tube with clot factor (NA citrate - blue top tube), followed by centrifugation at 3000rpm for 30 minutes. The supernatant (plasma) will then be collected, aliquoted, and stored at -80°C until further processing.
Genetic Analysis from Blood Samples: To gather information about AD variant genes, including APOE-ε4, we may send the coded blood samples for genotyping in-house at the MGH Center for Computational and Integrative Biology (per their published Mass General Brigham Members Genotyping rates). Results regarding the genotypic data will be securely stored in encrypted and password-protected devices per MGB requirements. No personal identifiers will be shared. Participants will not be made aware of their AD gene risk status.
Rigor and Reproducibility: The clinical study will follow institutional and federal guidelines for clinical research. All delirium assessments will be conducted by trained researchers. All source documents will be securely stored in encrypted and password protected devices in accordance with MGB requirements.
These study procedures will allow us to complete data analysis towards our objective of investigating the impact of sleep/circadian disruption on POD risk by defining the preoperative and postoperative profile of amyloid, tau, and neurodegeneration (ATN) biomarkers and proteomic signatures (inflammatory and metabolic) in older patients undergoing major non-cardiac surgery.
The Targeted/Planned enrollment for the proposed clinical study is consistent with the ethnic and racial composition of Suffolk County, MA. Please see below.
American Indian and Alaska Native - 0.7 Native Hawaiian and Other Pacific Islander - 0.2 Asian - 9.3 Black, not Hispanic or Latino - 24.3 White, not Hispanic or Latino - 45.2 Hispanic or Latino - 23.3 Two or more races - 3.7 Female - 51.7
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cohort will complete a series of blood sample donations (both intraoperatively and postoperatively) as well as complete daily neurocognitive assessments at baseline and on PODs 1 - 3.
Incidence of Delirium
Outcome will be assessed using the Confusion Assessment Method (CAM)
Time frame: From postoperative day 1 to postoperative day 3
Severity of Delirium
CAM: Minimum Score=0, Maximum Score=19, Higher Scores: indicate increased severity of delirium
Time frame: From postoperative day 1 to postoperative day 3
Delirium-free Days
CAM
Time frame: Up until postoperative day 3, or up until postoperative day 7 or discharge for patients who are delirious beyond postoperative day 5
Postoperative Cognitive Status
Telephone Montreal Cognitive Assessment (tMoCA): Minimum Score=0, Maximum Score=22, Higher Scores: indicate better cognitive function
Time frame: Months 1, 3, and 12 after surgery
Postoperative Insomnia Symptom Severity
Insomnia Severity Index, with lower scores being considered better
Time frame: Baseline and months 1, 3, and 12 after surgery
Postoperative Sleep Quality
Pittsburgh Sleep Quality Index, with lower scores being considered better
Time frame: Baseline and months 1, 3, and 12 after surgery
Postoperative Sleepiness
Epworth Sleepiness Scale, with lower scores being considered better.
Time frame: Baseline and months 1, 3, and 12 after surgery
Postoperative Depression
Assessed via Geriatric Depression Scale with lower scores being considered better.
Time frame: Baseline and months 1, 3, and 12 after surgery
Postoperative Anxiety
Assessed via Generalized Anxiety Disorder - 7 with lower scores being considered better
Time frame: Baseline and months 1, 3, and 12 after surgery
Postoperative Physical Function
Functional Activities Questionnaire with lower scores being better
Time frame: Baseline and months 1, 3, and 12 after surgery
Postoperative Physical Frailty
FRAIL Scale with lower scores being better
Time frame: Baseline and months 1, 3, and 12 after surgery
Postoperative Social Function
UCLA Loneliness Scale with lower scores being better
Time frame: Baseline and months 1, 3, and 12 after surgery
Blood Delirium Biomarkers - IL-6
Blood samples including whole blood and serum will be collected to define the pre and post-operative profiles of IL-6 biomarkers
Time frame: Day of surgery up until postoperative day 3
Blood Delirium Biomarkers - C-reactive protein
Blood samples including whole blood and serum will be collected to define the pre and post-operative profiles of C-reactive protein biomarkers
Time frame: Day of surgery up until postoperative day 3
Blood Delirium Biomarkers - Tau-PT181
Blood samples including whole blood and serum will be collected to define the pre and post-operative profiles of Tau-PT181 biomarkers
Time frame: Day of surgery up until postoperative day 3
Blood Delirium Biomarkers - Tau-PT217
Blood samples including whole blood and serum will be collected to define the pre and post-operative profiles of Tau-PT217 biomarkers
Time frame: Day of surgery up until postoperative day 3
Length of Hospital Stay
Medical Record Review
Time frame: Date of hospital admission up until date of discharge, assessed up to 30 days
Plan to share: Yes — Patient specimens and data may be shared with individuals who are members of the IRB-approved research team or approved for sharing within the MGB network.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data may be shared with collaborators once the study has been completed.
Access criteria: IRB approved research team members or approved collaborators within MGB.
Started Sep 2023 (actual). Primary completion is estimated for Sep 2026, 36 months after the start.
Of 180 non-industry observational studies under Emergence Delirium, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 36 months is above that.
Counting every sponsor, half of 180 studies reached it within 21 months; a quarter within 10 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →